Synlett 2012; 23(11): 1564-1574
DOI: 10.1055/s-0031-1290425
account
© Georg Thieme Verlag Stuttgart · New York

Process Research and Development for Heterocyclic p38 MAP Kinase Inhibitors

Oliver R. Thiel*
Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA, Fax: +1(805)3754532   eMail: othiel@amgen.com
,
Michal Achmatowicz
Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA, Fax: +1(805)3754532   eMail: othiel@amgen.com
,
Robert M. Milburn
Chemical Process Research and Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA, Fax: +1(805)3754532   eMail: othiel@amgen.com
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 17. Februar 2012

Accepted after revision: 26. März 2012

Publikationsdatum:
11. Juni 2012 (online)


Preview

Dedicated to Professor Barry M. Trost on the occasion of his 70th birthday.

Abstract

The need to access different heterocyclic cores as part of p38 MAP kinase inhibitors led to the discovery and development of several efficient approaches to three separate classes of heterocycles, namely phthalazines, pyrazolopyridinones, and triazolopyridines. This account summarizes our studies in this field in a comprehensive fashion.

1 Introduction

2 Synthesis of Phthalazine-Based p38 Inhibitors

2.1 Synthesis of Clinical Candidate 2

2.2 Synthesis of Clinical Candidate 3

3 Synthesis of Pyrazolopyridinone-Based p38 Inhibitors

4 Synthesis of Triazolopyridine-Based p38 Inhibitors

4.1 Synthesis through Pd-Catalyzed Benzhydrazide Couplings

4.2 Synthesis through Pd-Catalyzed Benzhydrazone Couplings

5.0 Conclusions